PSA velocity in conservatively managed BPH: Can it predict the need for BPH-related invasive therapy?

Chaidir Arif Mochtar, Lambertus A.L.M. Kiemeney, M. Pilar Laguna, Frans M.J. Debruyne, Jean J.M.C.H. De La Rosette

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

OBJECTIVE. To study the value of PSA velocity (PSAV) to predict benign prostatic hyperplasia (BPH) progression in patients managed with α1-blockers or watchful waiting (WW). METHODS. Nine hundred and forty two BPH patients treated with α1-blocker or WW were reviewed. PSAV was defined as: (PSAt-PSAb)/(t/12); where PSAt = PSA at time of follow-up (t, in months), PSAb = PSA at baseline. PSAt was taken from the 1 year follow-up visit or, if not present, from the next available visit with a maximum of 24 months. RESULTS. Five hundred and ninety five patients (234 α1-blocker, 361 WW) were included in the analyses. PSAV range was -5.24 to 43.06 ng/ml/year in α1-blocker patients and -6.11 to 19.55 ng/ml/year in WW patients (median: 0.01 ng/ml/year). PSAV was stratified into tertiles (Stable/Decrease/Increase). There were no significant differences in retreatment-free survival and the risk of BPH-related invasive therapy between the tertiles in both treatment groups. CONCLUSIONS. PSAV did not predict BPH progression in either α1-blocker treated patients or WW group.

Original languageEnglish
Pages (from-to)1407-1412
Number of pages6
JournalProstate
Volume66
Issue number13
DOIs
Publication statusPublished - 13 Sep 2006

Keywords

  • Adrenergic alpha-blockers
  • Benign prostatic hyperplasia
  • Prostate-specific antigen
  • Treatment outcome

Fingerprint Dive into the research topics of 'PSA velocity in conservatively managed BPH: Can it predict the need for BPH-related invasive therapy?'. Together they form a unique fingerprint.

Cite this